Judith Abrams
Keine laufenden Positionen mehr
Profil
Judith Abrams worked as Head-Therapeutic, Bone & Joint Diseases at Amgen, Inc. and Head-Otezla Global Clinical Submission at Celgene Corp.
She also worked as Vice President-Clinical Development at NPS Pharmaceuticals, Inc. and Head-Early Clinical Development at Novartis Pharmaceuticals Corp.
Additionally, she worked as Vice President-Medical & Science Inflammation at Novo Nordisk, Inc. and Chief Medical Officer at CorMedix, Inc. and Editas Medicine, Inc. Dr. Abrams earned a doctorate degree from the University of Toronto Faculty of Medicine.
Ehemalige bekannte Positionen von Judith Abrams
| Unternehmen | Position | Ende |
|---|---|---|
| EDITAS MEDICINE, INC. | Technik-/Wissenschafts-/F&E-Leiter | 01.05.2020 |
| CORMEDIX INC. | Technik-/Wissenschafts-/F&E-Leiter | 24.08.2017 |
| AMGEN INC. | Corporate Officer/Principal | - |
| CELGENE | Corporate Officer/Principal | - |
Novartis Pharmaceuticals Corp.
 Novartis Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology Novartis Pharmaceuticals Corp. develops, manufactures, and markets prescription drugs. It manufactures and markets prescription drugs used to treat a number of diseases and conditions including cardiovascular, dermatological, central nervous system, bone disease, cancer, organ transplantation, psychiatry, infectious disease, and respiratory. The company was founded in 1996 and is headquartered in East Hanover, NJ. | Corporate Officer/Principal | - |
Ausbildung von Judith Abrams
| University of Toronto Faculty of Medicine | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 3 |
|---|---|
| CORMEDIX INC. | Health Technology |
| EDITAS MEDICINE, INC. | Health Technology |
| AMGEN INC. | Health Technology |
| Private Unternehmen | 4 |
|---|---|
Novo Nordisk, Inc.
 Novo Nordisk, Inc. BiotechnologyHealth Technology Novo Nordisk, Inc. operates diabetes care company. It offers biopharmaceuticals, chronic weight management, human growth hormone therapy and hemophilla management services. The firm also provides rare bleeding disorders, growth hormone related disorders, and women's health. The company was founded in 1982 and is headquartered in Plainsboro, NJ. | Health Technology |
NPS Pharmaceuticals, Inc.
 NPS Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology NPS Pharmaceuticals, Inc. developed drugs for bone and mineral disorders. It also developed Natpara for the treatment of adult hypoparathyroidism. The company was founded by Hunter Jackson and Thomas N. Parks on October 22, 1986 and is headquartered in Bedminster, NJ. | Health Technology |
Novartis Pharmaceuticals Corp.
Novartis Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology Novartis Pharmaceuticals Corp. develops, manufactures, and markets prescription drugs. It manufactures and markets prescription drugs used to treat a number of diseases and conditions including cardiovascular, dermatological, central nervous system, bone disease, cancer, organ transplantation, psychiatry, infectious disease, and respiratory. The company was founded in 1996 and is headquartered in East Hanover, NJ. | Health Technology |
Celgene Corp.
 Celgene Corp. BiotechnologyHealth Technology Celgene Corp. is an integrated global biopharmaceutical company, which engages in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases. Its primary commercial stage products include Revlimid, Pomalyst, Imnovid, Otezla, Abraxane, and Vidaza. The company was founded by David Stirling and Sol Barer in 1986 and is headquartered in Summit, NJ. | Health Technology |
